Effect of Acarbose on Long-Term Prognosis in Acute Coronary Syndromes Patients with Newly Diagnosed Impaired Glucose Tolerance

Journal of Diabetes Research
Peng YunHu Xiao

Abstract

To investigate the effect of acarbose therapy on the long-term prognosis of patients with acute coronary syndromes (ACS) complicating newly diagnosed impaired glucose tolerance (IGT). 135 patients hospitalized for ACS who had been newly diagnosed with IGT were randomly assigned to acarbose group (150 mg/day, n = 67) or control group (no acarbose, n = 68). All cases in each group were given the same elementary treatment. Mean follow-up was 2.3 years. The incidence of major adverse cardiovascular event (MACE) and carotid intima-middle thickness (CIMT) were statistically analyzed. During the mean follow-up of 2.3 years, the risk of recurrent MACE in acarbose group was decreased significantly compared with that in control group (26.67% versus 46.88%, P < 0.05); at the same time, thickening of the CIMT was significantly slower than the control group ((1.28 ± 0.42) mm versus (1.51 ± 0.64) mm, P < 0.05). Acarbose can effectively reduce the risk of MACE in ACS patients with newly diagnosed IGT, simultaneously retarding the progression of carotid intima-media thickness.

References

Jul 24, 2003·JAMA : the Journal of the American Medical Association·Jean-Louis ChiassonUNKNOWN STOP-NIDDM Trial Research Group
Mar 11, 2004·Diabetic Medicine : a Journal of the British Diabetic Association·R J HeineM-R Taskinen
Apr 10, 2004·Stroke; a Journal of Cerebral Circulation·Markolf HanefeldTheodora Temelkova-Kurktschiev
Dec 13, 2005·International Journal of Cardiology·Uwe Zeymer
Mar 1, 2008·Cardiovascular Drugs and Therapy·Markolf HanefeldCarsta Koehler
Jan 22, 2009·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Markolf HanefeldJean-Louis Chiasson
Jul 31, 2009·BMC Endocrine Disorders·Ralph A DefronzoDevjit Tripathy
Feb 11, 2010·Journal of Diabetes Science and Technology·Mikhail Kosiborod, Prakash Deedwania
Oct 12, 2010·QJM : Monthly Journal of the Association of Physicians·A A TahraniA A Fryer
May 6, 2011·Diabetes Care·Eberhard StandlAntonio Ceriello
Apr 18, 2012·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Eberhard Standl, Oliver Schnell
Nov 14, 2012·Nutrition Research·Eunice Mah, Richard S Bruno
Apr 20, 2014·Cardiovascular Diabetology·Eberhard StandlJaakko Tuomilehto
Nov 25, 2014·Cardiology in Review·Murugapathy VeerasamyVijay Kunadian

❮ Previous
Next ❯

Methods Mentioned

BETA
hormone replacement therapy
pharmacotherapies

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.